Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 13, 1999

View Archived Issues

Key proteomics patents issued to Oxford GlycoSciences

Licensing opportunity from Peptech: anti-TNF antibodies with a range of therapeutic applications

Banyu reviews new product pipeline

New cysteine protease inhibitors from SB for osteoporosis, arthritis, etc.

Hybridon develops antisense oligonucleotides to thymidylate synthase

Sydnonimine derivatives for cardiovascular disorders presented by Chugai

Taiho synthesizes novel compounds for bone metabolism disorders

Novel condensed pyridazines claimed by Takeda for allergic conditions

Peripherally selective kappa-opioid agonists in early development at Warner-Lambert

Excellent clinical results reported for ID Biomedical's rapid MRSA test; February filing announced

Seven-day treatment with AIT-082 leads to memory improvement in elderly volunteers

Scios AD research partnership with Lilly extended

Generic smoking cessation aid receives tentative FDA approval

Medarex receives milestone payment from Centocor related to HuMAb-Mouse technology

GelTex reports success with first- and second-generation cholesterol-lowering compounds

Nankai University team describes new compound with antileukemia activity

New antibiotic isolated and characterized at the Institute of Microbial Chemistry in Tokyo

Antibiotic produced by unidentified fungus shows activity against resistant bacteria

FDA advisory committee reaches positive conclusions regarding Chirocaine

Temodal receives positive recommendation for one indication from FDA advisory committee

First vaccine for Lyme disease now available from SB in the U.S.

PathoGenesis puts development of TB drug on hold

European study establishes long-term efficacy and safety of alprostadil alfadex

Medeva acquires license for scleroderma Rx from Connetics

Priority review status granted for Merck & Co.'s COX-2 inhibitor

PAF antagonist safe but not effective in the treatment of ulcerative colitis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 22, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...